Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq of pancreata from KRasG12D/RosaMycER treated with Tamoxifen for different times

ABSTRACT: RNAseq of pancreata from KRasG12D/RosaMycER treated with Tamoxifen for different times

PROVIDER: PRJEB35067 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNAseq of pancreata from KRasG12D/RosaMycER treated with Tamoxifen for different times

Project description:Experiment designed to study the effect of deregulated myc on pancreatic cancer progression and regression. In the KRasG12D/RosaMycER mouse model KRas and MycER are expressed exclusively in the pancreas, but MycER activity depends on Tamoxifen presence. RNAseq was preformed on pancreata from mice treated with Tamoxifen as follows: 1- Normal food. 2- Tamoxifen food 2 weeks. 3- Tamoxifen food 2 weeks, followed by normal food 1 day. 4- Tamoxifen food 2 weeks, followed by normal food 3 days.

2020-01-06 | E-MTAB-8467 | biostudies-arrayexpress

RNAseq of pancreatas from KRasG12D/RosaMycER treated with Tamoxifen for different times. MycOFF short times.

Project description:Experiment designed to study the effect of deregulated myc on pancreatic cancer progression and regression. In the KRasG12D/RosaMycER mouse model KRas and MycER are expressed exclusively in the pancreas, but MycER activity depends on Tamoxifen presence. RNAseq was preformed on pancreatas from mice treated with Tamoxifen as follows: 1-Tamoxifen food 2 weeks. 2- Tamoxifen food 2 weeks, followed by normal food 6 hours day. 3- Tamoxifen food 2 weeks, followed by normal food 12 hours.

2023-03-31 | E-MTAB-9564 | biostudies-arrayexpress

RNAseq of pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ treated with Tamoxifen for 12h

Project description:Experiment designed to study the effect of 1 or 2 copies of deregulated myc on transcriptional profile during pancreatic cancer progression. In the KRasG12D/RosaMycER mouse model KRas and MycER are expressed exclusively in the pancreas, but MycER activity depends on Tamoxifen presence. RNAseq was preformed on pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ mice treated 12 hours with Tamoxifen.

2022-06-08 | E-MTAB-10807 | biostudies-arrayexpress

RNAseq of cell line from pancreas from KRasG12D/RosaMycER mouse treated with Tamoxifen

Project description:Experiment designed to study the effect of deregulated myc on pancreatic cancer progression and regression. In the KRasG12D/RosaMycER mouse model KRas and MycER are expressed exclusively in the pancreas, but MycER activity depends on Tamoxifen presence. For this experiment a mouse was treated with Tamoxifen during 3 weeks, the pancreas was collected and the epithelial cells were grown in vitro in the presence of 4-OHT (4-Hydroxytamoxifen, active form of Tamoxifen). RNAseq were preformed on the cell line treated as follows: 1- 4-OHT all the time. 2- EtOH 6h. 3- EtOH 12h. 4- EtOH 18h.

2023-03-31 | E-MTAB-8693 | biostudies-arrayexpress

RNAseq of pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ treated with Tamoxifen for 12h

Project description:RNAseq of pancreatas from KRasG12D/RosaMycER+/- or KRasG12D/RosaMycER+/+ treated with Tamoxifen for 12h

| PRJEB46823 | ENA

Transcription profiling of pancreata from Ptf1a-Cre;LSL-KrasG12D and Ptf1a-Cre;LSL-KrasG12D;RelAfl/fl mice

Project description:Oncogene-induced senescence in early mPanIN lesions depends on intact RelA function in vivo. We investigated the difference in gene expression between KrasG12D pancreata with and without deletion of RelA. Pancreata from 7 day old mice were prepared, RNA was isolated and Affymetrix microarray expression analysis was performed.

2017-06-01 | E-MTAB-1036 | biostudies-arrayexpress

Expression data of caerulein-treated wild-type mice and KrasG12D-mutated mice at different stages of pancreatic regeneration after inflammatory injury

Project description:Consecutive caerulein injections induce an acute pancreatitis in mice. Here, we recorded gene expression levels at different stages of pancreatic regeneration in wild-type mice as well as KrasG12D-mutated mice. Tissue was collected from mice pancreata, cell sorting was not performed. t=0h refers to the time where caerulein was injected. control referes to NaCl-treated samples (no caerulein). 13 time points were used for wild-type mice, 9 time points were used for KrasG12D-mutated mice. Multiple replicates were generated for each time point. We used Affymetrix GeneChip Mouse Gene 1.0 ST arrays.

2016-07-03 | E-GEOD-65146 | biostudies-arrayexpress

Expression data of caerulein-treated wild-type mice and KrasG12D-mutated mice at different stages of pancreatic regeneration after inflammatory injury

2016-01-01 | GSE65146 | GEO

Bulk RNAseq of primary CD34+ HSPCs in Myeloproliferative neoplasms patients receiving tamoxifen

Project description:TAMARIN study is a Phase II, multicenter, single arm A’herns design clinical trial assessing tamoxifen’s safety and activity in reducing molecular markers of disease burden in MPN.The primary outcome (≥50% allele burden reduction at 24 weeks) was met by 3/37 patients; 5/37 additional patients showed ≥25% reductions. CD34+ HSPCs were collected from responders and non-respondersin the baseline line and 24W after tamoxifen treatment. RNAseq was performed to investigate the molecular signature about tamoxifen sensitivity and pharmacological mechanism of tamoxifen in MPN patients.

2023-10-02 | GSE172022 | GEO

RNAseq of CD31-/CD45- pneumocytes after 4 weeks of KRasG12V activation by tamoxifen

Project description:We report the RNAseq data obtained from 50.000-100.000 CD31-/CD45- pneumocytes isolated by FACS from mice harboring a normal dose or one extra copy of the Sirt1 gene, and a tamoxifen-inducible oncogenic KI alelle of KRasG12V after 4 weeks of tamoxifen treatment. Pneumocytes with the activated form of the inducible KRasG12V oncogene sere selected making use of the reporter gene LacZ (located next to the oncogene in the same polycistronic mRNA), by loading CD31-/CD45- pneumocytes with the LacZ-activated fuorogenic molecule FDG prior to FACS sorting.

2018-06-25 | GSE115179 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data